Export 28 results:
Sort by: Author Title Type [ Year  (Asc)]
Bosseila, M., A. EL Shakankiry, N. Kassem, and W. Elmetenawy, "Serum squamous cell carcinoma antigen as a marker of disease activity in Psoriasis", pan Arab league of Dermatologists , vol. 11, issue 1, 2000.
EL Shakankiry, A., O. Khashaba, A. A. Shaltout, N. Kassem, K. Abdelhady, and O. Ezzat, "Placental Expression & Serum Concentrations of Cytokeratin 19 in Pre-eclampsia ", Medical Journal of Cairo University , vol. 70, issue 2, 2002.
M. Metwally, I., S. A. Hussein, O. El Diwany, and N. Kassem, "Predictors of Prognostic outcome in patients with Psoriatic Arthritis", Egyptian Dermatologists Journal , vol. 24, issue 1, 2002.
Mostafa, B., M. Farid, H. Abdel Ghany, and N. Kassem, "Assessment of Erythropoiesis in renal anemia using soluble transferrin receptor,", Medical Journal of Cairo University , vol. 71, issue 3, 2003.
Safwat, E., T. ElNahas, H. Metwally, R. Abdel Motagally, and N. Kassem, "Palliative fractionated radiotherapy for bone metastasis: Clinical& Biological assessment of single vs multiple fractions", Journal of the Egyptian Nat.Cancer Inst. , vol. 19, issue 1, pp. 21-27, 2007.
Kassem, N., "Cancer Stem Cells: from Identification to Eradication (review article)", Egyptian National Cancer Institute , vol. 20, issue 3, 2008.
ElGhoneimy, E., M. Mostafa, N. Kassem, T. ElNahas, D. Habib, and H. Sedrak, Circulating P53 antibodies in patients with colorectal carcinoma : relation to clinico-pathological features and tumor markers, , 2009.
Azim, H. A., E. Isaak, E. Elsissy, R. Khalifa, A. Mohamed, and N. Kassem, CK19 as a predictor of micrometastasis in breast cancer patients, , 2009.
Kassem, N., A. A. Hamid, T. Attia, S. Baathallah, S. Mahmoud, Moemen, E, E. Safwat, Khala, f M, and O. r Shake, "Novel mutations of the nucleophosmin (NPM-1) gene in Egyptian patients with acute myeloid leukemia: a pilot study.", Egypt Natl Canc Inst., vol. 23, issue 2, pp. 73-8, 2011.
Fawzy El-Sayed, K, S. Paris, S. Becker, N. Kassem, H. Ungefroren, F. Fändrich, J. Wiltfang, and C. Dörfer, "Isolation & characterization of multipotent postnasal stem/progenitor cells from human alveolar bone proper", J.Craniomaxillofac.surg. , vol. 40, issue 8, pp. 735-42, 2012.
M.Kassem, N., A. G. Fahmy, M. Dosoky, and N. Medhat, CEBPA gene expression in Egyptian patients with AML, , 2013.
AbdelKader, Y., G. Emera, E. Safwat, H. A.Kassem, and N. Kassem, "The KRAS StripAssay for detection of KRAS mutation in Egyptian patients with colorectal cancer (CRC): A pilot study", Journal of the Egyptian National Cancer Institute , vol. 25, issue 1, pp. 37–41, 2013. kras.pdf
Kassem, N., H. Zawam, H. Kassem, and T. Nahas, "A descriptive study of plasma cell dyscrasias in Egyptian population", Journal of the Egyptian National Cancer Institute, vol. 26, issue 2, pp. 67-71, 2014. 1-s2.0-s1110036213000940-main.pdf
M Fawzy El-Sayed, K., S. Paris, C. Graetz, N. Kassem, M. Mekhemar, H. Ungefroren, F. Fändrich, and C. Dörfer, "Isolation & characterization of human gingival margin-derived STRO-1/MACS+ & MACS-cell populations", International Journal of Oral Science , 2014.
Saadeldin, M. K., H. Shawer, A. Mostafa, N. M. Kassem, A. Amleh, and R. Siam, New genetic variants of LATS1 detected in urinary bladder and colon cancer., , 2014.
ELDemerdah, D., M. Mattar, N. E. L. Husseiny, A. A. El Aziz, and N. Kassem, "P0053 Expression of the GM-CSF gene and anti GM-CSF antibodies in egyptian adults with acute myeloid leukaemia and myelodysblastic syndromes", European Journal of cancer , vol. 50, pp. 23, 2014.
Abdel-Malek, R., S. El-Deeb, H. A. Kassem, F. A. Nasser, and N. Kassem, "Philadelphia-Positive B-Acute Lymphoblastic Leukemia: Does it Differ from Philadelphia-Negative One in Egyptian Populations?", International Journal of Hematology and Oncology, vol. 27, issue 3, pp. 197-200, 2017.
Kassem, N. M., A. M. Ayad, N. M. ElHusseiny, D. M. El-Demerdash, H. A. Kassem, and M. M. Mattar, "Role of Granulocyte-Macrophage Colony-Stimulating Factor in Acute Myeloid Leukemia/Myelodysplastic Syndromes.", Journal of global oncology, vol. 4, pp. 1-6, 2018. Abstract

PURPOSE: Granulocyte-macrophage colony-stimulating factor (GM-CSF) cytokine stimulates growth, differentiation, and function of myeloid progenitors. We aimed to study the role of GM-CSF gene expression, its protein, and antibodies in patients with acute myeloid leukemia/myelodysplastic syndromes (AML/MDS) and their correlation to disease behavior and treatment outcome. The study included 50 Egyptian patients with AML/MDS in addition to 20 healthy volunteers as control subjects.

PATIENTS AND METHODS: Assessment of GM-CSF gene expression was performed by quantitative real-time polymerase chain reaction. GM-CSF proteins and antibodies were assessed by enzyme-linked immunosorbent assay.

RESULTS: There was significant decrease in GM-CSF gene expression ( P = .008), increase in serum level of GM-CSF protein ( P = .0001), and increase in anti-GM-CSF antibodies ( P = .001) in patients with AML/MDS compared with healthy control subjects. In addition, there was a significant negative correlation between serum levels of GM-CSF protein and initial peripheral blood blasts, percentage as well as response to therapy.

CONCLUSION: Any alteration in GM-CSF gene expression could have implications in leukemogenesis. In addition, GM-CSF protein serum levels could be used to predict outcome of therapy. GM-CSF antibodies may also play a role in the pathogenesis of AML/MDS. The use of these GM-CSF parameters for disease monitoring and as markers of disease activity needs further research.

Kassem, N. M., sahar sharaf, A. Abdelaziz, M. Mohsen, H. A. Kassem, S. El Khateeb, N. Medhat, B. Nagdy, R. Abdel Moneim, and M. Abdulla, "Towards Validation of Targeted Next-Generation Sequencing on Formalin Fixed Paraffin Embedded Colorectal Cancer Tissues in Egyptian Population: A Pilot Study with Feasibility and Challenges", International Journal of Cancer and Treatment, vol. 1, issue 1, pp. 20-29, 2018.
M., A. - E. F., H. E. A., M. M. T., H. A. Kassem, and N. M. Kassem, "C/EBPA AS A BIOMARKER GENE IN CANCER CELL AND ITS RELATION TO NATURAL ANTICANCER COMPOUNDS", Plant Archives, vol. 19, issue 2, pp. 2693-2700, 2019.
Talima, S., H. Kassem, and N. Kassem, "Chemotherapy and targeted therapy for breast cancer patients with hepatitis C virus infection.", Breast cancer (Tokyo, Japan), vol. 26, issue 2, pp. 154-163, 2019. Abstract

BACKGROUND: Hepatitis C virus infection (HCV) is a major health problem in Egypt. Breast cancer is the most common cancer among Egyptian women. Considering that both diseases are frequent in the Egyptian population, it is likely that many women are affected by both.

PURPOSE: To evaluate patient safety and applicability of chemotherapy in chronic hepatitis C virus-infected patients with breast cancer.

SUBJECTS AND METHODS: We performed retrospective survey of 58 Egyptian patients diagnosed with both diseases. We retrospectively investigated the baseline patient and tumor characteristics, the toxicities of chemotherapy, and the changes in HCV viral load before and after chemotherapy, in addition to treatment received for HCV infection.

RESULTS: Forty-four (75.9%) out of the 58 patients received chemotherapy with or without trastuzumab and one patient received lapatinib. We reported 2 patients who had HCV viral reactivation. Treatment with trastuzumab or Lapatinib was not associated with elevation in liver enzymes or change in HCV RNA viral load. Treatment discontinuation occurred in 31.8% (14/44) of patients due to complications. Dose reductions and/or dose delays were common (27.2%). Elevated liver enzymes were developed in 20 out of 44 (45.5%) patients who received chemotherapy. Three patients received antiviral treatment concomitant with chemotherapy with no significant complications.

CONCLUSIONS: Greater attention should be paid to the possibility of complications including HCV reactivation, fulminant hepatitis, and interrupted chemotherapy treatments in breast cancer patients with chronic HCV infection receiving immunosuppressive drugs. Close monitoring of patients with breast cancer and HCV infection should be done.

Kassem, N. M., W. S. Makar, H. A. Kassem, S. Talima, M. Tarek, H. Hesham, and M. A. El-Desouky, "Circulating miR-34a and miR-125b as Promising non Invasive Biomarkers in Egyptian Locally Advanced Breast Cancer Patients.", Asian Pacific journal of cancer prevention : APJCP, vol. 20, issue 9, pp. 2749-2755, 2019. Abstract

Background: Breast cancer (BC) is the second most common cancer worldwide. MicroRNAs are a group of
non-coding, single stranded RNAs of ~ 22 nucleotides, which regulate gene expression at the post-transcriptional level.
Circulating miRNAs have been found as potential blood based predictive biomarkers. Purpose: we aim to evaluate
miR-34a and miR-125b to predict outcome from neoadjuvant chemotherapy in Egyptian BC patients. Methodology:
Quantitative assessment of plasma miR-34a and miR-125b expression was performed by qRT-PCR. Thirty nine
newly diagnosed locally advanced BC female patients with 10 age and sex matched healthy volunteers were included
in the study. Results: We performed ROC curve analysis to evaluate the diagnostic value for the miR-34a with
AUCs = 0.995, cutoff point of 2.57 sensitivity 97.4%, specificity 100%, PPV 100%, NPV 83.3% and accuracy 97.7%.
miR-125b had AUC = 0.68 and a cutoff point of 8.69 with sensitivity 66.7%, specificity 70.0%, PPV 90.6%, NPV
41.2% and accuracy 73.5%. miR-34a expression were significantly higher in BC patients compared to controls with p
value <0.001*. Also, miR-34a expression level was significantly higher in patients with progressive disease with P value
=0.03*. However, miR-125b expression levels were insignificantly higher in responsive patients with p value = 0.2.
Conclusion: miRNAs are crucial candidates for novel molecular targeted therapies due to their capability to regulate
numerous genes in molecular pathways. Our data suggest that circulating miR-34a and miR-125b expression levels
could be promising highly accurate non-invasive biomarkers in diagnosing BCs. miR-34a can predict chemotherapeutic
resistance associated with higher expression levels in non-responsive patients.

Kassem, N. M., G. Emera, H. A. Kassem, N. Medhat, B. Nagdy, M. Tareq, R. Abdel Moneim, M. Abdulla, and W. H. El Metenawy, "Clinicopathological features of Egyptian colorectal cancer patients regarding somatic genetic mutations especially in KRAS gene and microsatellite instability status: a pilot study", Egyptian Journal of Medical Human Genetics, vol. 20, issue 20, pp. 1-9, 2019.